IDIBELL on the media

20160719_Direccio_Capella_3

Gabriel Capellá, director of IDIBELL

appointment of  Dr. Gabriel Capellá as director of IDIBELL.

20161221_Pujana_oncogene

Researchers describe the causes of resistance of tumor cells to therapy with mTOR inhibitors

Researchers from the proCURE ICO-IDIBELL breast cancer research group have first described why tumors adapt to and resist therapy with mTOR inhibitors, a treatment used in advanced stages of this cancer. The results of this international study, published in the journal Oncogene, sets new steps towards a more personalized selection of cancer therapies. The mTOR […]

20161220_Fabregat_oncogene

Researchers identify new suppressor effects of the NOX4 protein in liver cancer

Researchers of the TGF-beta and Cancer group of Bellvitge Biomedical Research Institute (IDIBELL), in collaboration with King’s College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells. The study has just been published in the journal […]

20161217_ConcertCorals

L’Hospitalet Christmas Concerts raise funds for IDIBELL

The City Council and the research center join forces to raise funds against intellectual disability 100 years Sinatra

Barcelona  Barcelones  12 12 2016   Economia    Jordi Portabella  director del Area d Investigacio i Coneixement de la Fundacio Bancaria  La Caixa   Carlos Trenchs  director general de Caixa Capital Risc  han presentado hoy  en el Palau Macaya   junto a los investigadores  los 20 proyectos seleccionados dentro del programa Caixaimpulse  ideado para la creacion de empresas biotecnologicas    FOTO DANNY CAMINAL

CaixaImpulse funds an IDIBELL project on hospital-acquired infections

Removal of antibodies with glycoconjugates Valuation and commercialisation, pending challenges

20161205_premis_valua

IDIBELL, a ”Company with Value”

On November 10th, the Bellvitge Biomedical Research Institute (IDIBELL) was awarded the “Company with Value” badge by Vàlua entities. This award rewards the collaboration and commitment of IDIBELL with this platform and with equal opportunities of all people. A “Company with Value” is a company committed to citizenship: a company that cares about the well-being […]

Diapositiva 1

The first analysis of Ewing’s sarcoma methyloma opens doors to new treatments

Researchers of the Sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, have first described the methylation profile of Ewing’s sarcoma (ES), a cancer of bone and soft tissues that mainly affects children and teenagers. Their analysis has unveiled the potential of the PTRF gene as a prognostic marker […]

20161129_Esteller_MejoresIdeas2

The EPICUP test, amongst the “Best ideas” 2016

Yesterday, November 28th, the ‘Best ideas 2016’ award ceremony, yearly organized by Diario Médico, took place in the National Theater of Catalonia (TNC). Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have been awarded a prize in this year’s edition, which aims to be a recognition of the work of professionals, institutions and companies that […]

20161117_Cognicio_Anhedonia

How does the brain of people who do not like music work?

Researchers from the Cognition and Cerebral Plasticity group of the Bellvitge Biomedical Research Institute and the University of Barcelona (IDIBELL-UB), in collaboration with researchers from the University of McGill (Montreal), have published a new study in which brain mechanisms associated to the lack of sensitivity to music are explained. The study, published by PNAS journal, […]

20161113_Tirado_Paella

11.850 euros for the investigation of children’s sarcoma in IDIBELL

The “Viladecans Against Cancer” Association delivers the funds raised during the second edition of its traditional Paella

Scroll to Top